Group 1 - The company, 永泰生物-B (06978), announced a proposed rights issue at a subscription price of HKD 2.5 per share, offering 1 rights share for every 5 existing shares held on the record date [1] - The maximum number of rights shares to be issued is 103 million shares (assuming no new shares are issued or repurchased before the record date) or 123 million shares (assuming all convertible bonds are converted and options are exercised), aiming to raise up to HKD 257 million or HKD 308 million respectively [1] - The net proceeds from the rights issue will be allocated as follows: approximately 54% for EAL® clinical trials, about 24% for expanding research and development expenses for other clinical indications of EAL®, and around 22% for general working capital [1] Group 2 - The company has applied to the Hong Kong Stock Exchange for the resumption of trading of its shares starting from 9:00 AM on September 22, 2025 [1]
永泰生物-B(06978)拟按“5供1”基准进行供股 9月22日复牌